A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

NCT03231878 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Adrenoleukodystrophy

Interventions

DRUG: MIN-102
DRUG: Placebos

Sponsor

Minoryx Therapeutics, S.L.